Head to Head Comparison: Tetralogic Pharmaceuticals Corp (TLOG) vs. Its Competitors
Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) is one of 95 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Tetralogic Pharmaceuticals Corp to similar companies based on the strength of its valuation, earnings, analyst recommendations, risk, profitability, institutional ownership and dividends.
This table compares Tetralogic Pharmaceuticals Corp and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
|Tetralogic Pharmaceuticals Corp Competitors||-910.58%||-183.99%||-27.07%|
Risk & Volatility
Tetralogic Pharmaceuticals Corp has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp’s peers have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.
This is a summary of recent ratings for Tetralogic Pharmaceuticals Corp and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
|Tetralogic Pharmaceuticals Corp Competitors||122||463||1157||11||2.60|
As a group, “Biotechnology” companies have a potential upside of 57.08%. Given Tetralogic Pharmaceuticals Corp’s peers higher possible upside, analysts plainly believe Tetralogic Pharmaceuticals Corp has less favorable growth aspects than its peers.
Institutional & Insider Ownership
2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are held by company insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Tetralogic Pharmaceuticals Corp and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals Corp||N/A||-$21.14 million||-0.02|
|Tetralogic Pharmaceuticals Corp Competitors||$224.52 million||$58.08 million||-1.13|
Tetralogic Pharmaceuticals Corp’s peers have higher revenue and earnings than Tetralogic Pharmaceuticals Corp. Tetralogic Pharmaceuticals Corp is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Tetralogic Pharmaceuticals Corp peers beat Tetralogic Pharmaceuticals Corp on 5 of the 9 factors compared.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Receive News & Stock Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related stocks with our FREE daily email newsletter.